Annabel Samimy

Douglas Tsao

Navann Ty

Serge Belanger

Madhumita Yennawar

Marc Goodman

Sam Eiber

Uy Ear

Charles

Doug Tsao

Mikaela Franceschina

Navann Ty Dietschi

- Evolus, Inc. (NASDAQ: EOLS) has named **Dr. Benjamin Eskenazi** as lead consultant for the national launch of its new **Evolysse™ filler line**.  **[1570562_20250922CL79419:0]** 
- The **FDA-approved Evolysse™ Form and Evolysse™ Smooth** mark Evolus' entry into the U.S. hyaluronic acid dermal filler market, representing a major technological breakthrough.  **[1570562_20250922CL79419:0]** 
- Dr. Eskenazi, a **board-certified plastic surgeon**, will leverage his expertise to support aesthetic providers, demonstrating Evolus' commitment to patient safety and education.  **[1570562_20250922CL79419:0]** **[1570562_20250922CL79419:1]** 
- The commercial launch of Evolysse™ Form and Evolysse™ Smooth is scheduled for **2025**, with Evolysse™ Sculpt planned for **2026** and Evolysse™ Lips for **2027**.  **[1570562_20250922CL79419:0]**

Evolus Appoints Dr. Benjamin Eskenazi as Lead Consultant for Evolysse™ Filler Launch

- Evolus announced **positive topline results** from a U.S. pivotal study for its Evolysse™ Sculpt injectable hyaluronic acid gel product, demonstrating **statistical superiority to Restylane®-Lyft**.  **[1570562_afdbb753a36b48788f774140deb56f3f_0]** **[1570562_afdbb753a36b48788f774140deb56f3f_1]** 
- The **Premarket Approval (PMA) application** for Evolysse™ Sculpt has been submitted to the U.S. Food and Drug Administration (FDA), with **approval expected in the second half of 2026**.  **[1570562_afdbb753a36b48788f774140deb56f3f_0]** **[1570562_afdbb753a36b48788f774140deb56f3f_1]** 
- Evolysse™ Sculpt is anticipated to be the **flagship brand** in the Evolysse™ collection, expanding Evolus's portfolio beyond Jeuveau® and targeting the highest-value segment of the dermal filler market.  **[1570562_afdbb753a36b48788f774140deb56f3f_0]** **[1570562_afdbb753a36b48788f774140deb56f3f_1]**

Evolus announces positive trial data for Evolysse™ Sculpt

Evolus (EOLS)